[1] Stoltz R, Cyong JC, Shah A, et al. Pharmacokinetic and safety evaluation of palonosetron, a 5hydroxytryptamine3 receptor antagonist, in U.S. and Japanese healthy subjects[J]. J Clin Pharmacol, 2004, 44(5): 520-531. DOI:10.1177/0091270004264641.
[2] Rojas C, Raje M, Tsukamoto T, et al. Molecular mechanisms of 5HT(3) and NK(1) receptor antagonists in prevention of emesis[J]. Eur J Pharmacol, 2014, 722: 26-37. DOI:10.1016/j.ejphar.2013.08.049.
[3] Aapro MS. Palonosetron as an antiemetic and antinausea agent in oncology[J]. Ther Clin Risk Manag, 2007, 3(6): 1009-1020.
[4] MoriVogt S, Blazer M. Palonosetron for prevention of chemotherapyinduced nausea and vomiting[J]. Expert Rev Anticancer Ther, 2013, 13(8): 919-936. DOI:10.1586/14737140.2013.814412.
[5] Eisenberg P, Mackintosh FR, Ritch P, et al. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatinbased chemotherapy: a doseranging clinical study[J]. Ann Oncol, 2004, 15(2): 330-337.
[6] Craver C, Gayle J, Balu S, et al. Palonosetron versus other 5-HT3 receptor antagonists for prevention of chemotherapyinduced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States[J]. J Med Econ, 2011, 14(3): 341-349. DOI:10.3111/13696998.2011.582908.
[7] 佟仲生, 李淑芬, 郑荣生, 等. 盐酸帕洛诺司琼注射液预防化疗引起恶心呕吐的临床疗效观察[J]. 中国肿瘤临床, 2014, 41(20): 1323-1327. DOI:10.3969/j.issn.1000-8179.20141171.
[8] Boccia R, Grunberg S, FrancoGonzales E, et al. Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapyinduced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial[J]. Support Care Cancer, 2013, 21(5): 1453-1460. DOI:10.1007/s00520-012-1691-5.
[9] Ikari Y, Ogata K, Nakashima Y, et al. Safety and pharmacokinetic evaluation of repeated intravenous administration of palonosetron 0.75 mg in patients receiving highly or moderately emetogenic chemotherapy[J]. Support Care Cancer, 2014, 22(7): 1959-1964. DOI:10.1007/s00520-014-2179-2.
[10] Kim KI, Lee DE, Cho I, et al. Effectiveness of palonosetron versus other serotonin 5HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy[J]. Ann Pharmacother, 2012, 46(12): 1637-1644. DOI:10.1345/aph.1R396.
[11] Aogi K, Sakai H, Yoshizawa H, et al. A phase Ⅲ openlabel study to assess safety and efficacy of palonosetron for preventing chemotherapyinduced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy[J]. Support Care Cancer, 2012, 20(7): 1507-1514. DOI:10.1007/s00520-011-1239-0.
[12] Celio L, Agustoni F, Testa I, et al. Palonosetron: an evidencebased choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy[J]. Tumori, 2012, 98(3): 279-286. DOI:10.1700/1125.12393.
[13] Fabi A, Malaguti P. An update on palonosetron hydrochloride for the treatment of radio/chemotherapyinduced nausea and vomiting[J]. Expert Opin Pharmacother, 2013, 14(5): 629-641. DOI:10.1517/14656566.2013.771166.
[14] Celio L, Denaro A, Canova S, et al. Clinical update on palonosetron in the management of chemotherapyinduced nausea and vomiting[J]. Tumori, 2008, 94(4): 447-452.
[15] Lorusso V, Giampaglia M, Petrucelli L, et al. Antiemetic efficacy of singledose palonosetron and dexamethasone in patients receiving multiple cycles of multiple daybased chemotherapy[J]. Support Care Cancer, 2012, 20(12): 3241-3246. DOI:10.1007/s00520-012-1469-9. |